

Lan Wang

Members of the WHO Expert Advisory Panel on The International Pharmacopoeia and Pharmaceuticals Preparations serving the INN Expert Group

Biography

Dr Lan Wang currently is Acting Director of Management Office of National Key Laboratory for Drug Regulatory Science. National Key Laboratory for Drug Regulatory Science is the only one national key laboratory of NMPA (National Medical Products Administration).

She has seventeen years' work experience in the field of quality control of biological products in the Institute for Biological Product Control of National Institutes for Food and Drug Control (NIFDC). She has held various positions in this institute which started from Acting Director of Monoclonal Antibodies Laboratory to Deputy Director of Institute for Biological Product Control. She is the expert of EDQM, and also the expert for INN committee of Chinese Pharmacopoeia Commission.

Her major research areas include quality control of antibody-based biotherapeutics and biosimilars, analytical methods elaboration and validation, specifications development and R&D of reference standards and system suitability standards for antibody-based biotherapeutics. Her team's work also provides technical supports for NMPA & Chinese Pharmacopoeia (CP) regulation and guideline setting.

Dr Wang has been playing a leading role in setting up a series of international advanced platforms for bioactivity determination of mAbs based on transgene technologies, quality similarity evaluation of mAb biosimilars, research on ADCs (Antibody Drug Conjugates) and so on.

She was trained by immunologist and achieved her Ph.D. on immunology in 2007 from the Health Science Center of Peking University, one of the top two universities in China.